Abstract
Benign prostatic hyperplasia and prostate cancer arise as a consequence of changes in the balance between cell division and differentiation. Little, however, is known about the control of this process. Stem cells are a small population of cells that divide occasionally to produce transit-amplifying cells that in turn produce the differentiated cell types of the tissue. It is believed that cancer cell proliferation is also driven by stem cells. We have shown that around one in 200 prostate epithelial cells have characteristics of stem cells and that these cells are contained within a population with a distinct keratin expression pattern. Work is now ongoing to identify markers for these cells that will allow us to study the role they play in prostatic disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Isaacs JT, Coffey DS . Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989; 2: 33–50.
Bonkhoff H, Remberger K . Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996; 28: 98–106.
Shamblott MJ et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci USA 1998; 95: 13726–13731.
Thomson JA et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145–1147.
Morrison SJ et al. Identification of a lineage of multipotent hematopoietic progenitors. Development 1997; 124: 1929–1939.
Potten CS, Loeffler M . Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110: 1001–1020.
Lavker RM, Sun TT . Epidermal stem cells: properties, markers, and location. Proc Natl Acad Sci USA 2000; 97: 13473–13475.
Morrison SJ, Weissman IL . The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity 1994; 1: 661–673.
Mezey E et al. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 2000; 290: 1779–1782.
Lagasse E et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000; 6: 1229–1234.
Poulsom R . Does bone marrow contain renal precursor cells? Nephron Exp Nephrol 2003; 93: e53–e57.
Bickenbach JR, Chism E . Selection and extended growth of murine epidermal stem cells in culture. Exp Cell Res 1998; 244: 184–195.
Morris RJ, Potten CS . Highly persistent label-retaining cells in the hair follicles of mice and their fate following induction of anagen. J Invest Dermatol 1999; 112: 470–475.
Cotsarelis G, Sun TT, Lavker RM . Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 1990; 61: 1329–1337.
Schermer A, Galvin S, Sun TT . Differentiation-related expression of a major 64 K corneal keratin in vivo and in culture suggests limbal location of corneal epithelial stem cells. J Cell Biol 1986; 103: 49–62.
Tsujimura A et al. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol 2002; 157: 1257–1265.
Reya T et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105–111.
Park CH, Bergsagel DE, McCulloch EA . Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst 1971; 46: 411–422.
Bruce WR, Van Der Gaag H . A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 1963; 199: 79–80.
Bonnet D, Dick JE . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730–737.
Verhagen AP et al. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 1992; 52: 6182–6187.
De Marzo AM et al. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 1998; 153: 911–919.
van Leenders GJ, Schalken JA . Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. Crit Rev Oncol Hematol 2003; 46 (Suppl): S3–S10.
Nagle RB et al. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res 1987; 47: 281–286.
Liu AY et al. Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate 1999; 40: 192–199.
English HF, Santen RJ, Isaacs JT . Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 1987; 11: 229–242.
Evans GS, Chandler JA . Cell proliferation studies in the rat prostate: II. The effects of castration and androgen-induced regeneration upon basal and secretory cell proliferation. Prostate 1987; 11: 339–351.
Verhagen AP et al. Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate 1988; 13: 25–38.
van der Kwast TH et al. Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. J Pathol 1998; 186: 406–409.
Hudson DL et al. Epithelial differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 2001; 49: 271–278.
Liu AY et al. Cell–cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci USA 1997; 94: 10705–10710.
McDonnell TJ et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940–6944.
Abrahamsson PA . Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999; 39: 135–148.
Bonkhoff H, Stein U, Remberger K . Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994; 25: 42–46.
Xue Y et al. Identification of intermediate cell types by keratin expression in the developing prostate. Prostate 1998; 34: 292–301.
van Leenders G et al. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000; 80: 1251–1258.
Lechner JF et al. Normal human prostate epithelial cell cultures. Methods Cell Biol 1980; 21B: 195–225.
Peehl DM, Stamey TA . Growth responses of normal, benign hyperplastic, and malignant human prostatic epithelial cells in vitro to cholera toxin, pituitary extract, and hydrocortisone. Prostate 1986; 8: 51–61.
Robinson EJ, Neal DE, Collins AT . Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate 1998; 37: 149–160.
Fry PM et al. Comparison of marker protein expression in benign prostatic hyperplasia in vivo and in vitio. BJU Int 2000; 85: 504–513.
Hudson DL et al. Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest 2000; 80: 1243–1250.
Sawicki JA, Rothman CJ . Evidence for stem cells in cultures of mouse prostate epithelial cells. Prostate 2002; 50: 46–53.
Kleinman HK et al. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 1982; 21: 6188–6193.
Petersen OW et al. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 1992; 89: 9064–9068.
Fong CJ et al. Reconstituted basement membrane promotes morphological and functional differentiation of primary human prostatic epithelial cells. Prostate 1991; 19: 221–235.
Cunha GR et al. Hormone-induced morphogenesis and growth: role of mesenchymal–epithelial interactions. Recent Prog Horm Res 1983; 39: 559–598.
Bayne CW et al. A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5 alpha-reductase. J Clin Endocrinol Metab 1998; 83: 206–213.
Collins AT et al. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 2001; 114: 3865–3872.
Lang SH et al. Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional matrigel culture. Cell Growth Differ 2001; 12: 631–640.
Fuchs E, Tumbar T, Guasch G . Socializing with the neighbors: stem cells and their niche. Cell 2004; 116: 769–778.
Jones PH, Watt FM . Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 1993; 73: 713–724.
Jones PH, Harper S, Watt FM . Stem cell patterning and fate in human epidermis. Cell 1995; 80: 83–93.
Adams JC, Watt FM . Changes in keratinocyte adhesion during terminal differentiation: reduction in fibronectin binding precedes alpha 5 beta 1 integrin loss from the cell surface. Cell 1990; 63: 425–435.
Hotchin NA, Kovach NL, Watt FM . Functional down-regulation of alpha 5 beta 1 integrin in keratinocytes is reversible but commitment to terminal differentiation is not. J Cell Sci 1993; 106 (Part 4): 1131–1138.
Artavanis-Tsakonas S, Rand MD, Lake RJ . Notch signaling: cell fate control and signal integration in development. Science 1999; 284: 770–776.
Milner LA et al. A human homologue of the Drosophila developmental gene, Notch, is expressed in CD34+ hematopoietic precursors. Blood 1994; 83: 2057–2062.
Lowell S et al. Stimulation of human epidermal differentiation by delta-notch signalling at the boundaries of stem-cell clusters. Curr Biol 2000; 10: 491–500.
Wang XD et al. Notch 1-expressing cells are indispensable for prostatic branching morphogenesis during development and re-growth following castration and androgen replacement. J Biol Chem 2004; 279: 24733–24744.
Greenberg NM et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439–3443.
Nemeth JA et al. Prostatic ductal system in rats: tissue-specific expression and regional variation in stromal distribution of transforming growth factor-beta 1. Prostate 1997; 33: 64–71.
Nemeth JA, Lee C . Prostatic ductal system in rats: regional variation in stromal organization. Prostate 1996; 28: 124–128.
Kundu SD et al. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)-TGF-beta type II dominant negative receptor. Prostate 2000; 43: 118–124.
Bhowmick NA et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848–851.
Reed JC . Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1–6.
Hockenbery D et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334–336.
Krajewski S et al. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994; 145: 1323–1336.
Moul JW et al. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996; 120: 159–166, discussion 166–167.
Colombel M et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993; 143: 390–400.
Yang A et al. p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305–316.
Mills AA et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398: 708–713.
Yang A et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714–718.
Signoretti S et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157: 1769–1775.
Sgambato A et al. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol 2000; 183: 18–27.
Goodell MA et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797–1806.
Terunuma A et al. Side population keratinocytes resembling bone marrow side population stem cells are distinct from label-retaining keratinocyte stem cells. J Invest Dermatol 2003; 121: 1095–1103.
Alvi AJ et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res 2003; 5: R1–R8.
Bhatt RI et al. Novel method for the isolation and characterisation of the putative prostatic stem cell. Cytometry 2003; 54A: 89–99.
Acknowledgements
D Hudson is funded by the Bob Champion Cancer Trust and the NCRI. Thanks to all my past co-authors who contributed to the work described within this review, in particular to John Masters and Adam Guy.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hudson, D. Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis 7, 188–194 (2004). https://doi.org/10.1038/sj.pcan.4500745
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500745
Keywords
This article is cited by
-
Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development
Protein & Cell (2012)
-
Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies
Journal of Experimental & Clinical Cancer Research (2010)
-
Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis
Oncogene (2008)
-
The intercellular adhesion molecule, cadherin-10, is a marker for human prostate luminal epithelial cells that is not expressed in prostate cancer
Modern Pathology (2008)
-
Identification of vitamin D receptor as a target of p63
Oncogene (2006)